Black Diamond Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation, all of which were approved by stockholders. No questions were submitted on the official business, and the meeting was adjourned after confirming voting outcomes.
-
Phase II results show silevertinib achieved a 60% objective response rate and 86% CNS response rate in frontline EGFR NCM non-small cell lung cancer, with a median PFS of 15.2 months and manageable safety profile. No new brain metastases developed during treatment.
-
Silevertinib, a fourth-generation EGFR inhibitor, shows strong efficacy and CNS activity in non-classical EGFR NSCLC and is advancing into a pivotal GBM trial. Key PFS data in NSCLC are expected in Q2 2024, with GBM trial enrollment starting soon and results anticipated in 2028.
Fiscal Year 2025
-
Silevertinib’s Phase II data in non-classical EGFR-mutant lung cancer showed a 60% response rate and strong CNS activity, with durability and PFS data expected in Q2 2026. Plans include FDA engagement, a pivotal trial, and a Phase II GBM study, supported by a strong financial runway.
-
Silevertinib demonstrated a 60% response rate and robust CNS activity in frontline NSCLC patients with non-classical EGFR mutations, with manageable toxicity and durable responses. A randomized phase II trial in newly diagnosed GBM patients with EGFR variant 3 will launch soon, leveraging silevertinib's broad EGFR inhibition and strong brain penetrance.
-
Silevertinib is advancing as a brain-penetrant EGFR inhibitor for non-small cell lung cancer and glioblastoma, targeting a broad range of mutations with promising early efficacy and tolerability. Key data updates and partnership decisions are expected in the coming quarters.
-
Silevertinib, a brain-penetrant EGFR inhibitor, is advancing in phase 2 for non-classical EGFR-mutant lung cancer and glioblastoma, with key data expected this quarter. The drug targets a broad mutation spectrum, with a $2B+ market opportunity and pivotal phase 3 planned next year.
-
A fourth-generation EGFR TKI is advancing in phase II for frontline non-small cell lung cancer, targeting non-classical mutations with strong CNS activity and a favorable safety profile. A pivotal phase III trial is planned, with accelerated approval possible by 2029. Key data readouts and regulatory updates are expected later this year.
-
The company is advancing its lead oral therapy, 1535, for non-classical EGFR mutant NSCLC, with a focus on frontline patients and broad mutation coverage. A recent partnership has extended cash runway, enabling pivotal development and a Q4 2024 data and FDA update.
-
BDTX-1535, an oral fourth-generation EGFR inhibitor, is advancing in NSCLC and GBM with broad activity across mutation types and a favorable safety profile. Key phase II data in frontline NSCLC and regulatory updates are expected in Q4 2024, with additional GBM data in 2025.
Fiscal Year 2024
-
A fourth-generation EGFR inhibitor is advancing through phase 2 trials, showing robust efficacy and favorable tolerability in both recurrent and frontline non-small cell lung cancer, especially for non-classical and resistant mutations. Regulatory updates and mature data are expected in 1Q25.
-
BDTX-1535 demonstrated promising activity and tolerability in phase 2 for non-small cell lung cancer, with a 30%-40% response rate and a manageable safety profile. Strategic focus and financial runway support pivotal development, with key data updates expected in 2025.
-
Initial Phase II data for BDTX-1535 in recurrent EGFR-mutant NSCLC show a 42% response rate at 200 mg, with durable responses and a favorable safety profile across diverse resistance mutations. The therapy demonstrates promise for both recurrent and frontline non-classical mutation populations.